A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression

NCT01536743 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
26
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Jonsson Comprehensive Cancer Center